Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
22.67
-0.12 (-0.50%)
Nov 5, 2024, 1:19 PM EST - Market open
Genmab Revenue
Genmab had revenue of 5.40B DKK in the quarter ending June 30, 2024, with 29.58% growth. This brings the company's revenue in the last twelve months to 19.02B, up 17.19% year-over-year. In the year 2023, Genmab had annual revenue of 16.47B with 13.57% growth.
Revenue (ttm)
19.02B DKK
Revenue Growth
+17.19%
P/S Ratio
n/a
Revenue / Employee
8,627,949 DKK
Employees
2,204
Market Cap
14.40B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 16.47B | 1.97B | 13.57% |
Dec 31, 2022 | 14.51B | 6.09B | 72.33% |
Dec 31, 2021 | 8.42B | -1.69B | -16.75% |
Dec 31, 2020 | 10.11B | 4.75B | 88.43% |
Dec 31, 2019 | 5.37B | 2.34B | 77.39% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Tenet Healthcare | 20.97B |
Universal Health Services | 15.42B |
Viatris | 15.24B |
Avantor | 6.82B |
Incyte | 4.08B |
Revvity | 2.71B |
Exact Sciences | 2.61B |
Natera | 1.36B |
GMAB News
- 11 minutes ago - Genmab to Present at Jefferies London Healthcare Conference - GlobeNewsWire
- 1 hour ago - Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 1 hour ago - Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting - Business Wire
- 21 days ago - Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024 - GlobeNewsWire
- 4 weeks ago - Major Shareholder Announcement - GlobeNewsWire
- 5 weeks ago - Grant of Restricted Stock Units and Warrants to Employees in Genmab - GlobeNewsWire
- 7 weeks ago - Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial - Business Wire
- 7 weeks ago - Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewsWire